NEW YORK (GenomeWeb) – MDxHealth today said that it has signed a deal to buy NovioGendix, a firm developing a liquid biopsy test for prostate cancer, for $8.8 million. 

Based in Nijmegen, Netherlands, NovioGendix was spun out of Radboud University Medical Center in 2007 and provides diagnostic tests for prostate, bladder, kidney, and other urologic cancers. Its main focus is on developing a liquid biopsy test for prostate cancer that can identify patients at low risk for the disease. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.